¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Lateral inhibition"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • central lateral nucleus
    °¡ÂÊÁß½ÉÇÙ, Á߽ɿÜÃøÇÙ
  • lateral
    °¡ÂÊ-, ¿ÜÃø-
  • lateral antebrachial cutaneous nerve
    °¡ÂʾƷ¡ÆÈÇǺνŰæ, ¿ÜÃøÀü¿ÏÇǽŰæ
  • lateral brachial cutaneous nerve
    °¡ÂÊÀ§ÆÈÇǺνŰæ, ¿ÜÃø»ó¿ÏÇǽŰæ
  • lateral canthus
    °¡ÂÊ´«±¸¼®, ¿Ü¾È°¢
  • lateral cerebral fossa
    ´ë³ú°¡ÂÊ¿À¸ñ, ´ë³úÃø¿Í
  • lateral chain
    °ç»ç½½
  • lateral conjugate paralysis
    °¡ÂÊÁֽø¶ºñ, ¿ÜÃøÁֽø¶ºñ
  • lateral corporal fold
    ¸öÅë°¡ÂÊÁÖ¸§
  • lateral corticospinal tract
    °¡ÂʰÑÁúô¼ö·Î, ¿ÜÃøÇÇÁúô¼ö·Î
  • lateral decubitus
    ¿·´©¿ò, Ãø¿ÍÀ§, ¿·´©¿îÀÚ¼¼
  • lateral decubitus position
    ¿·´©¿îÀÚ¼¼, ¸ð·Î´©¿îÀÚ¼¼
  • lateral epicondylitis
    °¡ÂÊÀ§°üÀýÀ¶±â¿°, ¿ÜÃø»ó°ú¿°
  • lateral gastrocnemius bursa
    °¡ÂÊÀåµýÁö±ÙÁÖ¸Ó´Ï, ¿ÜÃøºñº¹±Ù³¶
  • lateral geniculate body
    °¡Âʹ«¸­Ã¼, ¿ÜÃø½½»óü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • selective inhibition
    ¼±ÅþïÁ¦
  • migration inhibition test
    À̵¿¾ïÁ¦°Ë»ç, À̵¿ÀúÁö°Ë»ç
  • reciprocal inhibition psychotherapy
    »óÈ£¾ïÁ¦Á¤½Å¿ä¹ý
  • amyotrophic lateral sclerosis
    ±ÙÀ°À§Ãà°¡ÂʰæÈ­Áõ
  • lateral sacral artery
    °¡ÂʾûÄ¡µ¿¸Æ
  • lateral gastrocnemius bursa
    °¡ÂÊÀåµýÁö±ÙÁÖ¸Ó´Ï
  • lateral maxillary buttress
    °¡ÂÊÀ§ÅλÀ¹öÆÀº®
  • central lateral nucleus
    °¡ÂÊÁß½ÉÇÙ
  • lateral canthus
    °¡ÂÊ´«±¸¼®
  • lateral chain
    (¢¡side chain) °ç»ç½½
  • lateral nasal cartilage
    °¡ÂÊÄÚ¿¬°ñ
  • lateral decubitus
    ¿·´©¿ò, Ãø¿ÍÀ§, ¿·´©¿îÀÚ¼¼
  • lateral cerebral fossa
    ´ë³ú°¡ÂÊ¿À¸ñ
  • lateral corporal fold
    ¸öÅë°¡ÂÊÁÖ¸§
  • retrograde lateral plantar artery flap
    ¿ªÇà°¡Âʹ߹ٴڵ¿¸ÆÇÇÆÇ, ¿ªÇà¿ÜÃøÁ·Àúµ¿¸ÆÇÇÆÇ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Internal inhibition
    ³»ºÎ¾ïÁ¦(Үݻåäð¤)
  • PETINIA => particle-enhanced turbidimetric inhibition immunoassay
    ÀÔÀÚÁõ´ëºñʾïÁ¦¸é¿ªÃøÁ¤(¹ý)
  • afferent inhibition
    ±¸½É¼º ¾ïÁ¦(Ï´ãýàõåäð¤)
  • agar gel precipitin inhibition test
    ÇÑõ°Öħ°­¼Ò ÀúÁö½ÃÇè(¡­ ˽áÈðæò­ãËúÐ).
  • agglutination inhibition test
    ÀÀÁý¾ïÁ¦½ÃÇè(¡­åäð¤ãËúÐ).
  • allogen(a)ic inhibition
    µ¿Á¾¼¼Æ÷ÀúÁö(¡­á¬øàðæò­).
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦ (¡­åäð¤)
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition antibody
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • hemagglutination inhibition test
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • hemagglutination inhibition test =HIT
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • facultative inhibition
    ÀӽþïÁ¦
  • feedback inhibition
    µÇ¸ÔÀÓ¾ïÁ¦(åäð¤).
  • feedfoward inhibition
    ÇÇÀ̵å-Æ÷¿öµå ¾ïÁ¦(åäð¤)
  • fluoresence inhibition test
    Çü±¤¾ïÁ¦½ÃÇè, Çü±¤ÀúÁö½ÃÇè
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • haemagglutination inhibition test
    Ç÷±¸ÀÀÁýÀúÁö½ÃÇè(¡­îÁò­ãËúÐ).
  • haemagglutination inhibition test
    Ç÷±¸ÀÀÁýÀúÁö½ÃÇè(?Ëø?ËàÌ´).
  • hemagglutination inhibition antibody
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • hemagglutination inhibition test
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
  • hemagglutination inhibition test =HIT
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • hemagglutination-inhibition (HI) test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Lateral segment
    °¡Âʱ¸¿ª
    [¿¾ ¿ë¾î] ¿ÜÃøÁß¿±±¸
  • Lateral segmental bronchus
    °¡Âʱ¸¿ª±â°üÁö
    [¿¾ ¿ë¾î] ¿ÜÃøÁß¿±Áö
  • Lateral segmental artery
    °¡Âʱ¸¿ªµ¿¸Æ
    [¿¾ ¿ë¾î] ¿ÜÃø±¸µ¿¸Æ
  • Lateral reticular nucleus
    °¡Âʱ׹°ÇÙ
    [¿¾ ¿ë¾î] ¿ÜÃø¸Á»óüÇÙ
  • Lateral muscular branch
    °¡ÂʱÙÀ°°¡Áö
    [¿¾ ¿ë¾î] ¿ÜÃø±ÙÁö
  • Lateral column
    °¡ÂʱâµÕ
    [¿¾ ¿ë¾î] ÃøÁÖ
  • Lateral column
    °¡ÂʱâµÕ [¿ÜÃø»Ô]
    [¿¾ ¿ë¾î] ÃøÁÖ
  • Lateral pterygoid m.
    °¡Âʳ¯°³±Ù
    [¿¾ ¿ë¾î] ¿ÜÃøÀ͵¹±Ù
  • Lateral pterygoid nerve
    °¡Âʳ¯°³±Ù½Å°æ
    [¿¾ ¿ë¾î] ¿ÜÃøÀ͵¹±Ù½Å°æ
  • Lateral splanchnic arteries
    °¡Âʳ»À嵿¸Æ
    [¿¾ ¿ë¾î] ¿ÜÃø³»À嵿¸Æ
  • Lateral intermuscular septum of thigh
    °¡ÂʳҴٸ®±ÙÀ°»çÀ̸·
    [¿¾ ¿ë¾î] ¿ÜÃø´ëÅð±Ù°£Áß°Ý
  • Lateral femoral cutaneous nerve
    °¡ÂʳҴٸ®ÇǺνŰæ
    [¿¾ ¿ë¾î] ¿ÜÃø´ëÅðÇǽŰæ
  • Lateral femoral circumflex artery
    °¡ÂʳҴٸ®ÈÖµ¹À̵¿¸Æ
    [¿¾ ¿ë¾î] ¿ÜÃø´ëÅðȸ¼±µ¿¸Æ
  • Lateral circumflex femoral vein
    °¡ÂʳҴٸ®ÈÖµ¹ÀÌÁ¤¸Æ
    [¿¾ ¿ë¾î] ¿ÜÃø´ëÅðȸ¼±Á¤¸Æ
  • Lateral ventricle
    °¡Âʳú½Ç
    [¿¾ ¿ë¾î] Ãø³ú½Ç
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • migration inhibition factor
    À̵¿ÀúÇØ ÀÎÀÚ(ì¹ÔÑîÁúªì×í­)
  • mixed inhibition
    È¥ÇÕÀúÇØ(ûèùêîÁúª)
  • multiple inhibition analysis
    ´ÙÁß(Òýñì)ÀúÇØ ºÐ¼®(îÁúªÝÂà°)
  • multivalent allosteric inhibition
    ´Ù°¡(Òýʤ) ¾Ë·Î½ºÅ׸®ÀúÇØ(îÁúª)
  • multivalent feedback inhibition
    ´Ù°¡(Òýʤ) µÇ¸ÔÀÓÀúÇØ(îÁúª)
  • noncompetitive inhibition
    ºñ°áÇÕ ÀúÇØ(ު̿ùêîÁúª)
  • parabolic inhibition
    Æ÷¹°¼±Çü(øØÚªàÊû¡) ÀúÇØ(îÁúª)
  • partial inhibition
    ºÎºÐ ÀúÇØ(Ý»ÝÂîÁúª)
  • polyvalent allosteric inhibition
    ´Ù°¡(Òýʤ) ¾Ë·Î½ºÅ׸® ÀúÇØ(îÁúª)
  • product inhibition
    »ê¹°ÀúÇØ(ß§ÚªîÁúª)
  • pseudofeedback inhibition
    À§(êÊ)µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • sequence feedback inhibition
    ¼­¿­(ßíÖª) µÇ¸ÔÀÓÀúÇØ(îÁúª)
  • substrate inhibition
    ±âÁúÀúÇØ (ÐñòõîÁúª)
  • suicide inhibition
    ÀÚ¸ê ÀúÇØ(í»ØþîÁúª)
  • total inhibition
    ÀüÀúÇØ(îïîÁúª)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
LVN lateral ventricular nerve; lateral vestibular nucleus; Licensed Visiting Nurse; Licensed Vocational ...
LAI assay Leukocyte Adherence Inhibition assay
MIF   1) Mllerian Inhibiting Factor
  2) Migrating Inhibition Factor
TBII TSH Binding Inhibiting(= Inhibition) Immunoglobulin
AGPI agar gel precipitin inhibition
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ITIM immunoreceptor tyrosine-based inhibition motif
IR Inhibition Rate
(125)I Inhibition of
IOR Inhibition of return
ICI Intracortical inhibition
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lateral ampullar nerve
    °¡ÂÊ ÆØ´ë ½Å°æ
  • lateral and protrusive excursion
    Ãø¹æ ¹× Àü¹æ Á¢ÃË ¿îµ¿
  • lateral angle of eye
    °¡ÂÊ ´« ±¸¼®
  • lateral anterior malleolar artery
    ¿ÜÀü¹æ Á·±Ù°ú µ¿¸Æ, Àü¿Ü°ú µ¿¸Æ
  • lateral aortic lymph node
    °¡ÂÊ ´ëµ¿¸Æ ¸²ÇÁÀý
  • lateral arcuate ligament
    °¡ÂÊ È°²Ã Àδë
  • lateral atlanto-occipital ligament
    °¡ÂÊ °í¸® µÚÅë¼ö Àδë
  • lateral atlantoaxial articulation
    ¿ÜÃø ȯÃà °üÀý
  • lateral balance training
    Ãø¹æ ¹ë·±½º ÈÆ·Ã
  • lateral basal brach
    °¡ÂÊ ¹Ù´Ú °¡Áö
  • lateral basal segment
    °¡ÂÊ ¹Ù´Ú ±¸¿ª
  • lateral bicipital groove
    °¡ÂÊ µÎ °¥·¡ ±Ù °í¶û
  • lateral border
    °¡ÂÊ ¸ð¼­¸®
  • lateral border movement
    Ãø¹æ ÇÑ°è ¿îµ¿
  • lateral border of tibia
    °ñ°£ ¿¬
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
noncompetitive inhibition <chemistry> A form of enzyme inhibition which cannot be reversed by increasing the amount of substrate in the reaction.
(09 Oct 1997)
substrate inhibition Inhibition of an enzyme activity by a substrate of the reaction catalyzed by that enzyme; often, this type of inhibition occurs at elevated substrate levels in which the substrate is binding to a second, non-active site on the enzyme.
(05 Mar 2000)
nonreciprocal contact inhibition <cell biology> Collision behaviour between different cell types in which one cell shows contact inhibition of locomotion and the other does not. An example is the interaction between sarcoma cells and fibroblasts (the former not being inhibited).
(18 Nov 1997)
density dependent inhibition of growth <cell culture> The phenomenon exhibited by most normal (anchorage dependent) animal cells in culture that stop dividing once a critical cell density is reached.
The critical density is considerably higher for most cells than the density at which a monolayer is formed, for this reason, most cell behaviourists prefer the term density dependent inhibition of growth as this avoids any confusion with contact inhibition of locomotion, a totally different phenomenon that is contact dependent.
(12 Jan 1998)
inhibition 1. Arrest or restraint of a process.
2. <psychology> The interference with or prevention of a behavioural or verbal response even though the stimulus for that response is present; in psychoanalysis the unconscious restraining of an instinctual process.
Origin: L. Inhibere = to restrain, habere = to hold
(04 Jul 1999)
inhibition factor <growth factor> A soluble, nondialysable factor that is produced by sensitised lymphocytes following exposure to a specific antigen. It inhibits macrophage migration and causes adherence.
It was originally defined on the basis of inhibition of emigration of mononuclear cells from capillary (haematocrit) tubes, more recently a 13 kD protein with migration inhibitory activity has been isolated.
Acronym: MIF
Synonym: inhibition factor.
(22 Sep 2002)
tissue thromboplastin inhibition time A test used to identify lupus anticoagulant; the thromboplastin source used in the prothrombin test is diluted to increase sensitivity to inhibitors.
(05 Mar 2000)
end product inhibition <biochemistry, physiology> The process of the end product of a particular metabolic reaction inhibiting an allosteric enzyme involved in that reaction as the reaction starts again, thus breaking the reaction cycle.
(09 Oct 1997)
enzyme inhibition theory of narcosis That narcotics inhibit respiratory enzymes by suppression of the formation of high energy phosphate bonds within the cell.
(05 Mar 2000)
uncompetitive inhibition An inhibitory effect on a metabolic function, such as an enzyme, not based on competition for the binding site of the naturally occurring substrate, but on a different effect on the molecule whose function is being inhibited.
(05 Mar 2000)
feedback inhibition <biochemistry, physiology> The process of the end product of a particular metabolic reaction inhibiting an allosteric enzyme involved in that reaction as the reaction starts again, thus breaking the reaction cycle.
(09 Oct 1997)
zone of inhibition <microbiology> The area of no bacterial browth around an antimicrobial agent in the disk-diffusion test.
(09 Oct 1997)
leukocyte adherence inhibition test Test for cell-mediated antitumour immunity and related serum blocking factors based on the finding that leukocytes from cancer patients, but not from controls, when mixed in vitro with antigenic extracts of tumours of the same histological type, undergo a diminution in their normal adherence to glass surfaces. Sera from tumour-bearing patients block the lai reaction of their own leukocytes or those of other patients with the same type of tumour.
(12 Dec 1998)
Amberg's lateral sinus line A line dividing the angle formed by the anterior edge of the mastoid process and the temporal line.
(05 Mar 2000)
amyotrophic lateral sclerosis A serious neurologic disease that results from the progressive degeneration of the motor neurons.
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á